Point72 Asset Management
MGX icon

Point72 Asset Management’s Metagenomi Therapeutics MGX Stock Holding History

Point72 Asset Management’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.7K Sell
11,726
-14,863
-56% -$23.1K ﹤0.01% 3689
2025
Q4 		$43.1K Buy
+26,589
New +$57.6K ﹤0.01% 3795
2024
Q3 		– Sell
-99,002
Closed -$404K – 2401
2024
Q2 		$404K Sell
99,002
-272,098
-73% -$1.87M ﹤0.01% 1487
2024
Q1 		$3.92M Buy
+371,100
New +$4.27M 0.01% 1052

Other funds holding MGX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management's MGX Position: Q1 2026 in Review

Point72 Asset Management reduced its Metagenomi Therapeutics (MGX) stake by 56% in Q1 2026, selling an estimated $23.1K and leaving 11,726 shares worth $15.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3689.

Point72 Asset Management first reported a position in MGX in Q1 2024 and has held it in 4 quarters since. The position peaked at $3.92M in Q1 2024. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

  • Point72 Asset Management held 11,726 shares of Metagenomi Therapeutics worth $15.7K as of Q1 2026.
  • Point72 Asset Management sold 14,863 Metagenomi Therapeutics shares in Q1 2026, an estimated $23.1K.
  • Metagenomi Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #3689 holding.
  • Point72 Asset Management first reported a position in Metagenomi Therapeutics in Q1 2024 and has held it in 4 quarters since.
  • Point72 Asset Management's Metagenomi Therapeutics position peaked at $3.92M in Q1 2024.
  • 48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.